[e-drug] Consumer perspectives

e-drug
1

E-DRUG: Consumer perspectives
-----------------------------------------------------------------------------------------

Dear Colleagues
I have been asked to compile some information on how the consumer view is being used in policy and research decisions alongside clinical data in South East Asia. I am specifically interested in how consumer views are being used to design the outcome measures for clinical trials, inform regulators on drug safety, including adverse drug reaction reporting, and inform insurers on the relative value of different therapies. I would be pleased to hear of any country experience of this reasonably new approach and I will share my subsequent findings on e-drug.

Thank you for your assistance

Kind regards
Lynn

Lynn Weekes
Chief Executive
NPS MedicineWise
Level 7, 418A Elizabeth St
Surry Hills 2010
Australia
+61413834438
lweekes@nps.org.au

2

E-DRUG: Consumer perspectives (2)
----------------------------------------------------------------------------------

Dear Lynn

In Brazil, the participation of civil society in the Health System management is a law mandate, and also related to research decisions. All Ethic Committes must have the participation of civil society, or consumers, if you prefer.

Our National Research Ethics Committe (http://conselho.saude.gov.br/web_comissoes/conep/index.html) has a magazine, with a number dedicated to this discussion (in Portuguese):
http://conselho.saude.gov.br/biblioteca/revistas/revista05.pdf

I hope this is helpfull.

Regards
Vera Luiza
National School of Public Health (en)
Brazil
vera@ensp.fiocruz.br